...to demonstrate a case of successful treatment Brentuximab vedotin of CD30-negative angioimmunoblastic T-cell lymphoma. The tumor cells did not have CD30 expression, but due to the presence of CD30 expression on healthy cells of the microenvironment, it was decided to use Brentuximab vedotin (Bv) as a salvage-therapy. On Bv therapy, a partial response was achieved with an improvement in the quality of life (13 injections were performed in total - 4 in combination with Bendamustine and 3 with Rituximab). Therapy was continued with lenalidomide, resulting in a complete response. This clinical case demonstrates that complete response was achieved by the effect of drugs on microenvironment but not on tumor cells, which emphasizes the immune dependence of this histological variant of PTCL.